A Phase 2 interventional study of REGN5381 and Placebo in Heart Failure, sponsored by Regeneron Pharmaceuticals. Terminated at 44 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies in Heart Failure with a site in Belgium — 27 open to participants now, 45 under way, 8 of them phase 3. Heart Failure · Belgium.
Among the 197 studies in Heart Failure with a site in Belgium, this one is the 105th largest by enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2024, is one of 23 in phase 2, and was the 176th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →27 of the 197 studies in Heart Failure with a site in Belgium are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Belgium, United States, France and 7 more countries
Ages 18+
Bayer · Sites in Belgium, United States, Argentina and 20 more countries
Ages up to 18
Fondazione Don Carlo Gnocchi ETS · Sites in Belgium, Italy, Portugal and 1 more country
Ages 18+
Ziekenhuis Oost-Limburg · Sites in Belgium
Ages 18+
Bayer · Sites in Belgium, United States, Argentina and 20 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 27 · Phase 3 44 · Phase 4 9
First in 1983; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 262 across the 155 interventional studies, 450 across the 42 observational. Of the 137 that completed or were terminated, 59 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 197 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06661876Universitaire Ziekenhuizen KU LeuvenCardiac RadiothErapy For hEart faiLure | 2026-12-31 |
| NCT07823998Jean-Benoît Le Polain de WarouxCoffee Use, Physical Activity and Symptomatic Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction and an ICD | 2027-04 |
| NCT07556588XVIVO PerfusionXVIVO Heart Transplant Study in Clinical Practice | 2027-05-15 |
| NCT07252856Fondazione Don Carlo Gnocchi ETSTranscultural Digital Solutions in Phase III Cardiac Rehabilitation | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 197 studies in Heart Failure with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
The aim of the study is to see how safe, tolerable, and effective the study drug is.
The study is looking at several other research questions, including:
Enrollment for the Part A2 low eGFR cohort has been closed
Key Inclusion Criteria
Sacubitril-valsartan treatment:
a. Treatment with sacubitril-valsartan at screening and at baseline permitted in Part A2 sacubitril-valsartan cohort and in Part B if supported by safety data from the Part A2 sacubitril-valsartan cohort as described in the protocol
Estimated (eGFR) levels:
Key Exclusion Criteria
Note: Other protocol-defined inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Single ascending dose cohort
Drug: REGN5381
Drug: Placebo
Single ascending dose cohort. Note: This group has been closed
Drug: REGN5381
Single ascending dose cohort. Note: This group has been closed
Drug: REGN5381
Note: This group has been closed
Drug: Placebo
Drug: REGN5381
Drug: REGN5381
Drug: Placebo
Single dose intravenous (IV) infusion
Single dose IV infusion
Fold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)
NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.
Time frame: Baseline, Day 8
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity
TEAEs are defined as those adverse events (AEs) with either initial onset after the first dose of study treatment or that worsen after the first dose of study treatment. The severity of an AE was graded according to the following scale: * Mild: Does not interfere in a significant manner with the participant's normal functioning level. * Moderate: Produces some impairment of functioning but is not hazardous to health. * Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participant's health. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section.
Time frame: Up to Week 16
Fold Change From Baseline in Circulating NT-proBNP
NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.
Time frame: Baseline, Days 15, 22, 29, 57, 85, 113
Change From Baseline in Systolic Blood Pressure (SBP)
Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Change From Baseline in Diastolic Blood Pressure (DBP)
Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Change From Baseline in Mean Arterial Pressure (MAP)
Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Change From Baseline in Heart Rate (HR)
Time frame: Day 1 (1,2,4,8hrs post-dose readings), Day 2 (24hrs post-dose readings 1,2,3), Day 3 (48hrs post-dose readings 1,2,3), Day 4 (72hrs post-dose readings 1,2,3), Day 5 (96hrs post-dose readings 1,2,3), Day 8, Day 15, Day 22, Day 29, Day 57, Day 85, Day 113
Concentration of Total REGN5381 in Serum
Time frame: Day 0 (pre-dose), Day 0 (post-dose), Days 1, 2, 3, 4, 7, 14, 21, 28, 56, 84, 112
Number of Participants With a Treatment-Emergent Anti-Drug Antibody (ADA) Response to REGN5381
Time frame: Up to Week 16
Maximum Titer Category of Participants With ADAs to REGN5381
Time frame: Up to Week 16
| Milestone | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Started | 35 | 9 | 19 | 9 | 17 |
| Received study drug | 35 | 9 | 19 | 9 | 17 |
| Not low egfr | 33 | 9 | 17 | 9 | 17 |
| Low egfr | 2 | 0 | 2 | 0 | 0 |
| Completed | 33 | 9 | 19 | 9 | 17 |
| Not completed | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 |
NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.
| fold change | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Fold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) | 0.95 ± 57.1 | 1.29 ± 37.1 | 0.97 ± 40.3 | 1.73 ± 58.2 | 1.08 ± 59.8 |
TEAEs are defined as those adverse events (AEs) with either initial onset after the first dose of study treatment or that worsen after the first dose of study treatment. The severity of an AE was graded according to the following scale: * Mild: Does not interfere in a significant manner with the participant's normal functioning level. * Moderate: Produces some impairment of functioning but is not hazardous to health. * Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participant's health. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section.
| Participants | Placebo: Not on SV, Not Low eGFR | Placebo: Not on SV, Low eGFR | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV, Not Low eGFR | REGN5381 100 mg: Not on SV, Low eGFR | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|---|---|
| Participants with at least one Mild TEAE | 4 | 1 | 1 | 1 | 0 | 3 | 2 |
| Participants with at least one Moderate TEAE | 3 | 0 | 0 | 1 | 0 | 3 | 0 |
| Participants with at least one Severe TEAE | 1 | 0 | 1 | 1 | 0 | 1 | 1 |
NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-baseline to Baseline, and it is assumed to follow a lognormal distribution.
| fold change | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Fold change from baseline to Day 15 | 1.13 ± 50.8 | 1.19 ± 25.0 | 1.15 ± 46.7 | 1.71 ± 68.0 | 1.26 ± 56.8 |
| Fold change from baseline to Day 22 | 1.00 ± 48.7 | 1.15 ± 37.2 | 1.11 ± 63.2 | 1.29 ± 63.0 | 0.93 ± 61.8 |
| Fold change from baseline to Day 29 | 1.11 ± 52.4 | 1.39 ± 65.5 | 1.20 ± 47.6 | 1.61 ± 62.5 | 1.07 ± 88.1 |
| Fold change from baseline to Day 57 | 1.07 ± 48.6 | 1.41 ± 37.2 | 0.84 ± 62.5 | 1.04 ± 40.4 | 0.96 ± 73.2 |
| Fold change from baseline to Day 85 | 1.04 ± 53.6 | 1.09 ± 35.4 | 0.91 ± 83.8 | 0.90 ± 50.3 | 0.82 ± 68.5 |
| Fold change from baseline to Day 113 | 1.01 ± 68.7 | 1.18 ± 22.1 | 0.82 ± 72.7 | 1.31 ± 32.9 | 0.90 ± 79.7 |
| millimeters of mercury (mmHg) | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Day 1 - 1 hour post-dose reading | 0.1 ± 12.65 | -7.7 ± 15.06 | 0.5 ± 12.70 | -10.9 ± 5.40 | -2.4 ± 7.77 |
| Day 1 - 2 hours post-dose reading | -6.6 ± 11.76 | -9.4 ± 15.13 | -14.8 ± 12.96 | -12.8 ± 11.19 | -11.8 ± 8.65 |
| Day 1 - 4 hours post-dose reading | -4.3 ± 13.93 | -11.0 ± 14.80 | -13.4 ± 12.94 | -16.8 ± 15.55 | -8.8 ± 7.37 |
| Day 1 - 8 hours post-dose reading | -6.2 ± 14.64 | -12.0 ± 9.03 | -11.6 ± 13.45 | -3.2 ± 11.73 | -11.2 ± 10.09 |
| Day 2 - 24 hours post-dose reading 1 | -3.9 ± 13.21 | -10.6 ± 10.57 | -10.2 ± 13.68 | -6.7 ± 12.97 | -7.3 ± 11.74 |
| Day 2 - 24 hours post-dose reading 2 | -6.5 ± 14.49 | -9.2 ± 9.02 | -12.1 ± 16.96 | -14.2 ± 14.59 | -6.8 ± 12.95 |
| Day 2 - 24 hours post-dose reading 3 | -2.7 ± 14.30 | -14.0 ± 6.19 | -9.8 ± 17.70 | -5.9 ± 14.62 | -6.1 ± 12.64 |
| Day 3 - 48 hours post-dose reading 1 | -3.5 ± 14.61 | -8.0 ± 11.03 | -1.3 ± 16.36 | -3.8 ± 13.56 | -2.5 ± 14.58 |
| Day 3 - 48 hours post-dose reading 2 | -2.2 ± 11.79 | -11.3 ± 9.21 | -6.2 ± 15.48 | -4.7 ± 13.96 | -3.3 ± 12.89 |
| Day 3 - 48 hours post-dose reading 3 | -4.2 ± 15.01 | -14.0 ± 5.24 | -5.4 ± 15.04 | -4.1 ± 10.12 | 0.4 ± 10.86 |
| Day 4 - 72 hours post-dose reading 1 | -3.8 ± 15.74 | -4.9 ± 14.23 | -4.4 ± 15.90 | -0.8 ± 15.95 | 0.6 ± 12.28 |
| Day 4 - 72 hours post-dose reading 2 | -2.6 ± 16.32 | -4.3 ± 12.11 | -1.5 ± 17.72 | -0.2 ± 22.37 | -1.8 ± 12.56 |
| Day 4 - 72 hours post-dose reading 3 | -2.8 ± 13.68 | -12.4 ± 6.44 | -8.2 ± 11.52 | 0.2 ± 23.52 | -2.5 ± 8.94 |
| Day 5 - 96 hours post-dose reading 1 | -1.9 ± 14.74 | -10.0 ± 5.70 | -1.5 ± 16.32 | -4.5 ± 9.29 | -1.2 ± 11.53 |
| Day 5 - 96 hours post-dose reading 2 | -1.3 ± 11.27 | -6.4 ± 15.11 | -5.5 ± 6.36 | -10.1 ± 7.43 | -4.5 ± 3.54 |
| Day 5 - 96 hours post-dose reading 3 | 0.7 ± 13.05 | — | — | -18.0 | — |
| Day 8 | -5.2 ± 12.22 | -2.4 ± 13.02 | 0.8 ± 13.66 | -6.5 ± 12.50 | -0.4 ± 11.38 |
| Day 15 | 0.0 ± 15.04 | -11.2 ± 17.34 | 4.9 ± 13.64 | 1.6 ± 19.20 | 3.9 ± 13.28 |
| Day 22 | 0.6 ± 13.97 | -5.6 ± 13.22 | 2.6 ± 13.99 | 3.3 ± 17.35 | 6.6 ± 15.60 |
| Day 29 | -1.6 ± 15.18 | -2.9 ± 12.45 | 2.2 ± 13.13 | 1.7 ± 15.76 | 2.6 ± 13.20 |
| Day 57 | 1.6 ± 15.33 | -5.1 ± 14.89 | 3.7 ± 11.88 | -3.0 ± 7.53 | -0.1 ± 10.80 |
| Day 85 | 0.5 ± 14.51 | -4.7 ± 11.49 | 3.6 ± 15.93 | -5.8 ± 15.18 | 1.9 ± 14.18 |
| Day 113 | 0.4 ± 15.70 | -6.8 ± 13.11 | 4.1 ± 19.26 | -2.6 ± 15.40 | 2.4 ± 13.70 |
| mmHg | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Day 1 - 1 hour post-dose reading | -1.5 ± 9.33 | -5.4 ± 7.86 | -1.0 ± 9.02 | -9.6 ± 8.79 | -1.0 ± 9.20 |
| Day 1 - 2 hours post-dose reading | -6.6 ± 8.12 | -5.7 ± 9.14 | -10.0 ± 9.98 | -8.1 ± 13.05 | -9.5 ± 9.34 |
| Day 1 - 4 hours post-dose reading | -3.9 ± 9.94 | -2.4 ± 6.88 | -8.8 ± 11.63 | -8.1 ± 10.88 | -7.4 ± 8.65 |
| Day 1 - 8 hours post-dose reading | -5.7 ± 8.51 | -6.1 ± 10.23 | -7.2 ± 10.74 | -3.1 ± 8.99 | -9.1 ± 9.60 |
| Day 2 - 24 hours post-dose reading 1 | -1.7 ± 8.20 | -3.4 ± 9.79 | -7.3 ± 10.94 | 0.6 ± 10.96 | -3.4 ± 8.82 |
| Day 2 - 24 hours post-dose reading 2 | -4.5 ± 8.84 | -4.7 ± 8.19 | -7.6 ± 10.86 | -8.8 ± 12.26 | -2.8 ± 11.33 |
| Day 2 - 24 hours post-dose reading 3 | -3.5 ± 9.77 | -1.8 ± 6.16 | -7.9 ± 13.23 | -7.2 ± 17.31 | -3.2 ± 13.24 |
| Day 3 - 48 hours post-dose reading 1 | -3.7 ± 9.87 | -6.0 ± 2.92 | 0.4 ± 10.98 | -6.6 ± 14.89 | 0.1 ± 10.68 |
| Day 3 - 48 hours post-dose reading 2 | -4.0 ± 9.48 | -6.4 ± 8.68 | -5.4 ± 10.74 | -3.3 ± 9.06 | -1.6 ± 10.78 |
| Day 3 - 48 hours post-dose reading 3 | -2.7 ± 10.00 | -5.4 ± 12.12 | -4.3 ± 10.15 | -0.2 ± 11.49 | 0.2 ± 10.32 |
| Day 4 - 72 hours post-dose reading 1 | -2.5 ± 11.78 | -2.6 ± 11.25 | -1.4 ± 10.49 | 3.6 ± 15.80 | 2.8 ± 8.87 |
| Day 4 - 72 hours post-dose reading 2 | -3.9 ± 11.02 | 0.3 ± 10.95 | -1.9 ± 10.45 | -0.6 ± 15.05 | -1.2 ± 12.13 |
| Day 4 - 72 hours post-dose reading 3 | -3.1 ± 10.25 | -1.8 ± 9.41 | -5.5 ± 10.33 | 3.0 ± 13.22 | -1.4 ± 10.08 |
| Day 5 - 96 hours post-dose reading 1 | -1.7 ± 10.87 | -2.3 ± 6.87 | 1.2 ± 10.01 | 1.6 ± 9.83 | 2.4 ± 7.59 |
| Day 5 - 96 hours post-dose reading 2 | -0.3 ± 6.44 | -1.3 ± 9.64 | -3.0 ± 12.73 | -6.3 ± 7.87 | 2.0 ± 16.97 |
| Day 5 - 96 hours post-dose reading 3 | 1.0 ± 3.46 | — | — | -6.0 | — |
| Day 8 | -3.8 ± 8.94 | -1.4 ± 10.14 | 0.1 ± 10.50 | -3.9 ± 9.54 | 0.1 ± 9.01 |
| Day 15 | 0.3 ± 11.28 | -1.6 ± 7.89 | 4.4 ± 7.63 | -2.3 ± 9.95 | -0.8 ± 10.51 |
| Day 22 | 0.4 ± 10.94 | -1.3 ± 9.56 | 1.3 ± 12.44 | -2.8 ± 7.36 | 0.9 ± 9.45 |
| Day 29 | -1.4 ± 11.18 | 3.8 ± 5.97 | -0.3 ± 10.39 | 1.0 ± 11.27 | 2.1 ± 11.58 |
| Day 57 | 0.3 ± 9.46 | -3.0 ± 7.14 | 2.1 ± 12.29 | -4.0 ± 8.03 | -1.2 ± 9.77 |
| Day 85 | 0.2 ± 9.99 | -0.8 ± 7.63 | 3.2 ± 13.16 | -2.8 ± 6.85 | -0.1 ± 10.75 |
| Day 113 | 0.2 ± 11.49 | -1.9 ± 5.23 | -0.9 ± 14.14 | -4.1 ± 11.20 | -0.6 ± 12.00 |
| mmHg | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Day 1 - 1 hour post-dose reading | -1.0 ± 9.21 | -6.2 ± 8.45 | -0.5 ± 8.83 | -10.0 ± 7.28 | -1.5 ± 7.77 |
| Day 1 - 2 hours post-dose reading | -6.6 ± 8.00 | -6.9 ± 9.97 | -11.6 ± 9.94 | -9.7 ± 11.87 | -10.3 ± 8.45 |
| Day 1 - 4 hours post-dose reading | -4.0 ± 10.13 | -5.3 ± 7.40 | -10.3 ± 9.92 | -11.0 ± 12.13 | -7.9 ± 6.85 |
| Day 1 - 8 hours post-dose reading | -5.8 ± 9.54 | -8.1 ± 8.83 | -8.7 ± 10.31 | -3.2 ± 8.75 | -9.8 ± 8.38 |
| Day 2 - 24 hours post-dose reading 1 | -2.4 ± 9.08 | -5.8 ± 8.03 | -8.3 ± 10.78 | -1.9 ± 11.15 | -4.7 ± 8.20 |
| Day 2 - 24 hours post-dose reading 2 | -5.2 ± 9.57 | -6.2 ± 7.56 | -9.1 ± 12.31 | -10.6 ± 12.82 | -4.1 ± 10.69 |
| Day 2 - 24 hours post-dose reading 3 | -3.2 ± 9.83 | -5.8 ± 5.29 | -8.5 ± 13.39 | -6.8 ± 16.11 | -4.2 ± 11.31 |
| Day 3 - 48 hours post-dose reading 1 | -3.6 ± 10.54 | -6.7 ± 4.80 | -0.2 ± 11.72 | -5.6 ± 13.73 | -0.8 ± 11.05 |
| Day 3 - 48 hours post-dose reading 2 | -3.4 ± 9.42 | -8.1 ± 7.52 | -5.7 ± 11.80 | -3.8 ± 10.51 | -2.2 ± 9.74 |
| Day 3 - 48 hours post-dose reading 3 | -3.2 ± 10.69 | -8.3 ± 9.12 | -4.6 ± 10.95 | -1.5 ± 10.52 | 0.2 ± 9.41 |
| Day 4 - 72 hours post-dose reading 1 | -2.9 ± 12.22 | -3.3 ± 10.77 | -2.4 ± 11.44 | 2.1 ± 15.61 | 2.0 ± 7.79 |
| Day 4 - 72 hours post-dose reading 2 | -3.5 ± 11.91 | -1.2 ± 9.96 | -1.8 ± 11.90 | -0.4 ± 17.25 | -1.4 ± 10.22 |
| Day 4 - 72 hours post-dose reading 3 | -3.0 ± 9.99 | -5.3 ± 6.49 | -6.4 ± 9.60 | 2.1 ± 16.31 | -1.8 ± 7.70 |
| Day 5 - 96 hours post-dose reading 1 | -1.8 ± 11.45 | -4.9 ± 5.21 | 0.3 ± 10.99 | -0.4 ± 8.14 | 1.2 ± 7.59 |
| Day 5 - 96 hours post-dose reading 2 | -0.7 ± 4.54 | -3.0 ± 10.42 | -3.8 ± 10.61 | -7.6 ± 6.57 | -0.2 ± 10.14 |
| Day 5 - 96 hours post-dose reading 3 | 0.9 ± 4.30 | — | — | -10.0 | — |
| Day 8 | -4.2 ± 9.37 | -1.8 ± 8.93 | 0.3 ± 10.61 | -4.8 ± 9.80 | -0.1 ± 7.38 |
| Day 15 | 0.2 ± 11.31 | -4.8 ± 9.49 | 4.6 ± 8.57 | -1.0 ± 12.47 | 0.8 ± 7.87 |
| Day 22 | 0.5 ± 11.00 | -2.7 ± 9.91 | 1.7 ± 11.68 | -0.8 ± 9.54 | 2.8 ± 9.97 |
| Day 29 | -1.5 ± 11.55 | 1.6 ± 6.74 | 0.6 ± 9.40 | 1.2 ± 11.86 | 2.3 ± 10.16 |
| Day 57 | 0.8 ± 10.48 | -3.7 ± 8.23 | 2.6 ± 11.52 | -3.7 ± 6.57 | -0.8 ± 9.22 |
| Day 85 | 0.3 ± 9.92 | -2.1 ± 7.04 | 3.3 ± 13.20 | -3.8 ± 9.14 | 0.6 ± 9.97 |
| Day 113 | 0.3 ± 11.52 | -3.5 ± 4.89 | 0.8 ± 14.63 | -3.6 ± 12.25 | 0.4 ± 10.36 |
| beats per minute | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Day 1 - 1 hour post-dose reading | -0.1 ± 8.27 | -7.1 ± 12.79 | -0.1 ± 13.42 | 3.9 ± 13.09 | -7.6 ± 12.85 |
| Day 1 - 2 hours post-dose reading | 3.7 ± 11.39 | -1.1 ± 8.57 | -1.4 ± 11.72 | 5.6 ± 16.52 | -3.5 ± 15.25 |
| Day 1 - 4 hours post-dose reading | 1.2 ± 10.81 | -1.4 ± 14.51 | -0.5 ± 10.82 | 3.3 ± 14.44 | -3.0 ± 15.25 |
| Day 1 - 8 hours post-dose reading | -0.3 ± 7.53 | -5.2 ± 11.72 | 0.9 ± 15.18 | 3.0 ± 10.31 | -1.5 ± 16.75 |
| Day 2 - 24 hours post-dose reading 1 | -3.6 ± 7.54 | -4.1 ± 12.68 | -6.1 ± 14.65 | 0.4 ± 12.45 | -2.5 ± 20.05 |
| Day 2 - 24 hours post-dose reading 2 | 0.4 ± 10.39 | -4.4 ± 9.32 | -6.9 ± 12.18 | 3.3 ± 20.11 | 0.2 ± 17.24 |
| Day 2 - 24 hours post-dose reading 3 | -0.7 ± 11.20 | -7.5 ± 12.95 | -2.9 ± 9.95 | 5.6 ± 17.18 | 1.2 ± 20.31 |
| Day 3 - 48 hours post-dose reading 1 | -1.8 ± 11.44 | -5.3 ± 9.84 | -4.1 ± 9.78 | 2.2 ± 16.20 | -1.3 ± 15.92 |
| Day 3 - 48 hours post-dose reading 2 | 0.1 ± 9.14 | -3.8 ± 11.81 | -5.3 ± 12.71 | 0.8 ± 17.20 | 2.4 ± 17.10 |
| Day 3 - 48 hours post-dose reading 3 | 3.0 ± 8.98 | -6.4 ± 13.45 | -0.5 ± 10.08 | 5.1 ± 11.73 | -0.4 ± 15.71 |
| Day 4 - 72 hours post-dose reading 1 | -1.4 ± 8.90 | -4.2 ± 13.69 | -6.5 ± 11.90 | 10.0 ± 6.04 | -3.6 ± 16.80 |
| Day 4 - 72 hours post-dose reading 2 | 0.0 ± 9.89 | -8.2 ± 11.30 | -4.3 ± 11.24 | 7.4 ± 8.80 | 3.2 ± 19.36 |
| Day 4 - 72 hours post-dose reading 3 | -1.5 ± 9.61 | -3.0 ± 5.81 | -3.5 ± 10.94 | 9.0 ± 13.50 | -2.0 ± 13.24 |
| Day 5 - 96 hours post-dose reading 1 | -0.2 ± 9.16 | -4.4 ± 10.10 | -4.1 ± 13.84 | 3.6 ± 7.11 | -1.4 ± 19.21 |
| Day 5 - 96 hours post-dose reading 2 | 1.2 ± 4.96 | 0.9 ± 6.57 | 10.0 ± 11.31 | 9.3 ± 7.34 | -6.0 ± 19.80 |
| Day 5 - 96 hours post-dose reading 3 | 3.3 ± 3.06 | — | — | -14.0 | — |
| Day 8 | 0.7 ± 10.02 | -7.8 ± 11.22 | -3.4 ± 11.69 | 4.6 ± 12.15 | 0.6 ± 15.83 |
| Day 15 | 1.6 ± 13.16 | -3.1 ± 11.13 | 3.5 ± 12.03 | -0.8 ± 12.04 | 0.6 ± 15.06 |
| Day 22 | 3.6 ± 10.61 | -7.5 ± 13.70 | 3.1 ± 16.45 | -2.3 ± 13.39 | -1.4 ± 14.73 |
| Day 29 | 2.8 ± 13.45 | -2.3 ± 14.30 | 2.1 ± 17.75 | -0.8 ± 16.87 | 3.1 ± 15.51 |
| Day 57 | 3.1 ± 12.40 | -2.1 ± 13.82 | -2.1 ± 16.59 | -3.9 ± 15.87 | 4.1 ± 16.27 |
| Day 85 | 2.3 ± 13.49 | 1.3 ± 13.51 | -2.4 ± 11.36 | -4.1 ± 19.17 | 3.5 ± 18.88 |
| Day 113 | 3.4 ± 12.93 | -4.4 ± 7.67 | 0.9 ± 10.30 | -0.6 ± 11.89 | 5.2 ± 22.74 |
| milligrams per liter (mg/L) | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|
| Day 0 (pre-dose) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Day 0 (post-dose) | 24.2 ± 5.90 | 28.1 ± 5.70 | 79.1 ± 17.5 |
| Day 1 | 18.4 ± 4.19 | 19.4 ± 3.76 | 62.5 ± 13.0 |
| Day 2 | 14.4 ± 3.14 | 16.6 ± 2.88 | 52.1 ± 10.6 |
| Day 3 | 13.2 ± 2.46 | 14.5 ± 2.80 | 44.1 ± 9.29 |
| Day 4 | 12.1 ± 2.36 | 12.8 ± 3.53 | 41.1 ± 10.3 |
| Day 7 | 9.08 ± 2.33 | 9.30 ± 3.04 | 32.7 ± 7.65 |
| Day 14 | 6.12 ± 2.02 | 6.29 ± 2.36 | 22.1 ± 5.30 |
| Day 21 | 4.15 ± 1.66 | 3.91 ± 2.47 | 15.4 ± 5.05 |
| Day 28 | 2.59 ± 1.30 | 2.28 ± 1.33 | 11.5 ± 4.18 |
| Day 56 | 0.0592 ± 0.112 | 0.0441 ± 0.111 | 2.55 ± 2.04 |
| Day 84 | 0 ± 0 | 0 ± 0 | 0.223 ± 0.472 |
| Day 112 | 0 ± 0 | 0 ± 0 | 0.00513 ± 0.0173 |
| Participants | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|
| Number of Participants With a Treatment-Emergent Anti-Drug Antibody (ADA) Response to REGN5381 | 0 | 0 | 2 |
| Participants | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|
| Low | 0 | 0 | 1 |
| Moderate | 0 | 0 | 1 |
| High | 0 | 0 | 0 |
Collected over From informed consent through end of study (approximately 203 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: Not on SV | 1/35 (2.9%) | 1/35 (2.9%) | 8/35 (22.9%) |
| Placebo: on SV | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| REGN5381 100 Milligrams (mg): Not on SV | 0/19 (0%) | 1/19 (5.3%) | 4/19 (21.1%) |
| REGN5381 100 mg: On SV | 0/9 (0%) | 3/9 (33.3%) | 7/9 (77.8%) |
| REGN5381 300 mg: Not on SV | 0/17 (0%) | 1/17 (5.9%) | 3/17 (17.6%) |
| Event | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 1/35 | 0/9 | 0/19 | 1/9 | 0/17 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/35 | 0/9 | 0/19 | 1/9 | 0/17 |
| PneumoniaInfections and infestations | 0/35 | 0/9 | 0/19 | 1/9 | 1/17 |
| Enterocolitis infectiousInfections and infestations | 0/35 | 0/9 | 1/19 | 0/9 | 0/17 |
| Acute myocardial infarctionCardiac disorders | 1/35 | 0/9 | 0/19 | 0/9 | 0/17 |
| PericarditisCardiac disorders | 1/35 | 0/9 | 0/19 | 0/9 | 0/17 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/35 | 0/9 | 0/19 | 0/9 | 0/17 |
| Event | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/35 | 1/9 | 0/19 | 3/9 | 0/17 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/35 | 0/9 | 0/19 | 3/9 | 0/17 |
| Blood creatinine increasedInvestigations | 1/35 | 0/9 | 0/19 | 2/9 | 0/17 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/35 | 0/9 | 0/19 | 2/9 | 0/17 |
| Alanine aminotransferase increasedInvestigations | 2/35 | 0/9 | 1/19 | 1/9 | 1/17 |
| Aspartate aminotransferase increasedInvestigations | 2/35 | 0/9 | 1/19 | 1/9 | 1/17 |
| Blood bilirubin increasedInvestigations | 1/35 | 1/9 | 0/19 | 0/9 | 0/17 |
| Blood bilirubin unconjugated increasedInvestigations | 0/35 | 1/9 | 0/19 | 0/9 | 0/17 |
| Blood uric acid increasedInvestigations | 0/35 | 0/9 | 0/19 | 1/9 | 0/17 |
| Lymphocyte count decreasedInvestigations | 0/35 | 0/9 | 0/19 | 1/9 | 0/17 |
The safety analysis set included all randomized participants who received any study drug.
| Age, Continuous(years) | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV | Total |
|---|---|---|---|---|---|---|
| Mean | 66.5 ± 8.18 | 61.4 ± 12.89 | 63.7 ± 8.87 | 63.9 ± 9.45 | 64.2 ± 9.93 | 64.7 ± 9.26 |
| Sex: Female, Male(Participants) | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV | Total |
|---|---|---|---|---|---|---|
| Female | 10 | 1 | 8 | 3 | 8 | 30 |
| Male | 25 | 8 | 11 | 6 | 9 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 35 | 9 | 19 | 9 | 17 | 89 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 35 | 9 | 19 | 9 | 17 | 89 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)(picogram per milliliter (pg/mL)) | Placebo: Not on SV | Placebo: on SV | REGN5381 100 Milligrams (mg): Not on SV | REGN5381 100 mg: On SV | REGN5381 300 mg: Not on SV | Total |
|---|---|---|---|---|---|---|
| Mean | 1843.3 ± 1200.43 | 1988.9 ± 1465.36 | 2136.3 ± 2032.70 | 1880.6 ± 1068.17 | 2193.6 ± 2141.33 | 1991.3 ± 1599.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Apr 2024 to primary completion in Sep 2025, 17 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vixticibart